Human leukemia-lymphoma (LL) cell lines represent an extremely important resource for research in a variety of fields and disciplines. As the cell lines are used as in vitro model systems in lieu of primary cell material, it is crucial that the cells in the culture flasks faithfully correspond to the purported objects of study. Obviously, proper authentication of cell line derivation and precise characterization are indispensable requirements to use as model systems. A number of studies has shown an unacceptable level of LL cell lines to be false. We present here the results of authenticating a comprehensively large sample (n = 550) of LL cell lines mainly by DNA fingerprinting and cytogenetic evaluation. Surprisingly, nearidentical incidences (ca 15%) of false cell lines were observed among cell lines obtained directly from original investigators (59/395: 14.9%) and from secondary sources (23/155: 14.8%) implying that most cross-contamination is perpetrated by originators, presumably during establishment. By comparing our data with those published, we were further able to subclassify the false cell lines as (1) virtual: cross-contaminated with and unretrievably overgrown by other cell lines during initiation, never enjoying independent existence; (2) misidentified: crosscontaminated subsequent to establishment so that an original prototype may still exist; or (3) misclassified: unwittingly established from an unintended (often normal) cell type. Prolific classic leukemia cell lines were found to account for the majority of cross-contaminations, eg CCRF-CEM, HL-60, JUR-KAT, K-562 and U-937. We discuss the impact of cross-contaminations on scientific research, the reluctance of scientists to address the problem, and consider possible solutions. These findings provide a rationale for mandating the procurement of reputably sourced LL cell lines and their regular authentication thereafter.
Introduction
The resource of immortalized cell lines derived from primary hematopoietic malignancies represents a valuable tool for understanding the biology of hematopoietic tumor cells. 1 Such continuous cell lines provide a ready inexhaustible source of homogeneous monoclonal cell populations which are free of 'contaminating' bystander cells (eg normal hematopoietic cells). However, a hidden disadvantage of leukemia-lymphoma (LL) cell lines is the relative ease with which they may be undetectibly cross-contaminated with other cell lines. Thus, when the putative cross-contaminant 'B' outgrows the recipient cell line 'A', B will inevitably replace A, stealing its identity and those of all descendants. In such instances the cell line would no longer represent its published description.
While this problem is not new -the long and painful history of cell line cross-contaminations has been reviewed elsewhere [2] [3] [4] -it seems to have been exacerbated by the ever increasing numbers and use of cell lines. 5 Alerted to the problem some 10 years ago, [6] [7] [8] we undertook the systematic authentication of human tumor cell lines received by our institute, including detailed investigation into the extent and origins of each cross-contamination detected. By exploiting a DNA fingerprint databank, we were initially able to compare more than 100 LL cell lines received from the original investigators or from secondary sources. Cytogenetic karyotyping complemented this DNA profiling and was particularly useful for cell lines for which a karyotype accompanied the initial report by the original investigators. Using this combination of analyses, we found that in total, 14.8% of the human hematopoietic cell lines received either from the original investigator or from secondary sources were cross-contaminated with another cell line and thus deemed false. 2 Since that preliminary survey we have expanded this effort by examining in detail the authenticities of all 550 human LL cell lines made available to us, based on our DNA fingerprint and cytogenetic data. Although unfortunately only a minority of investigators were prepared to provide requested cell lines, our survey covers the bulk of circulating LL cell lines. We present the results of these investigations.
Panel of cell lines analyzed
Altogether, we examined the authenticity of 550 human LL cell lines (taken here to include those derived from myeloma). These comprised 490 individual cell lines supplemented with 60 duplicate -or even triplicate and quadruplicateexamples, each collected from an independent source. Thus, for example, cell line U-937 was received from the original laboratory and from three other independent sources; similarly, cell lines CCRF-CEM, HL-60, K-562, TF-1, THP-1 and UT-7 were obtained from three to four laboratories each. For analysis, cell lines obtained from original investigators (primary sources; n = 395) or from independent laboratories (secondary sources; n = 155) have been treated separately.
Methods for authentication and identification of cell lines

Ascertainment of false cell lines
Cytogenetics and DNA fingerprinting are commonly used during cell line authentication, the respective methods enabling the detection of distinct, although overlapping groups of false cell lines. Although the effectiveness of both cytogenetics and DNA fingerprinting is somewhat diminished by the risk of false-positives or -negatives, errors affecting the respective methods arise independently permitting cross-verification (see below). Not unexpectedly, we find combining cytogenetics with DNA fingerprinting improves the unprompted detection of false cell lines. Of course, additional clues, emanating from a variety of studies, whether functional, immunological (notably hematopoietic cell surface markers), isoenzymatic, or morphological etc, inform all stages of authentication at the DSMZ. The logistical challenge for comparing fingerprints and karyotypes of several hundred LL cell lines was solved by setting up large and comprehensive databases of fingerprint banding patterns and of chromosomal aberrations.
DNA fingerprinting
As applied to human cell culture, current fingerprint technology provides an indispensable technique facilitating: (1) identification of new cell lines by comparison with donor DNA material, if available; (2) confirmation of identity at different passages; (3) evaluation of 'purity' of a given cell culture and quantitation of any admixture; (4) genomic characterization of human-animal hybrid cell lines; and (5) mapping of loss of heterozygosity of chromosomal regions (eg for detection of tumor suppressor genes).
Part of the non-coding DNA contains repetitive DNA blocks, 'mini-or microsatellites', up to several hundreds of base pairs in size. 9 The single-locus satellites are localized at specific sites on each human chromosome, while multi-locus satellite elements comprising short tandem repeats (STRs) are spread throughout the entire genome. 8, 10 Polymorphic variation in the sizes of the DNA repeats -variable numbers of tandem repeats (VNTR) -define the length of the alleles, which may be distinguished electrophoretically by the Southern blot or polymerase chain reaction (PCR) techniques. The likelihood of individuals displaying distinct (paternal/maternal-derived) pairs of allelic DNA fragments depends directly on the degree of polymorphic variation encountered in their host genetic populations at that locus and on the frequency of the alleles in question. In contrast, multilocus probes recognize large and complex mixtures of anonymous DNA fragments. Multi-locus fingerprints simultaneously provide a large amount of information with a high uniqueness value, a reason why this method is frequently used in paternity testing. A high level of uniqueness may be obtained by singlelocus fingerprinting when several highly polymorphic regions are analyzed. A drawback of DNA fingerprinting of both primary tumor cells and those adapted to in vitro culture is their tendency to sustain sizeable genomic deletions, resulting in loss of heterozygosity (LOH) for all heterozygous loci in the region affected.
The crucial question in the present context is whether a new cell line is authentic. Our approach to genetic authentication includes both PCR fingerprint methods using micro-and minisatellite loci, respectively. As described above, these probes all have considerable individualization potential. 11, 12 In order to facilitate cell line authentication and to minimize problems of false-negative and false-positive identification due to LOH, we applied the PCR technique to the amplification of human minisatellite loci, termed amplified fragment length polymorphism (AmpFLP) (Figure 1 ), in combination with the restriction fragment length polymorphism (RFLP) analysis using (GTG) 5 multi-locus fingerprinting. This sequential use of both fingerprint systems exploits the screening sensitivity of AmpFLP to shortlist candidate cross-contaminants which may then be checked using the higher accuracy of multi-locus RFLP analysis.
The VNTRs of various loci have been shown to span repeated DNA elements from 168 to over 4000 bp in length after PCR amplification. 13, 14 After accurate size determination of each allele, the data are entered into VNTR-specific databases as well as into a database containing all fragment sizes,
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Figure 1
Minisatelite DNA fingerprinting of K-562 cross-contaminants. After multiplex PCR amplification of the human VNTR markers Apo-B1, D1S80, D17S5 and D2S44 of the cell lines K-562, BLIN-1, DD, K051, RS-1 SAM-1, SPI-801 and SPI-802, the PCR products were analyzed for size determination using agarose gel electrophoresis. The banding pattern of the indicated cell lines revealed identical DNA profiles with exception of a second allele of D2S44 in the case of BLIN-1 and SAM-1, which show an amplifiable fragment of 2550 bp in size (white arrowheads). For further confirmation of cell line identity, a high resolution multi-locus DNA fingerprint was carried out using (GTG) 5 as a probe as described in detail elsewhere, 13, 14 confirming the results by showing identical fragment patterns for all cell lines (data not shown).
which is used for searches and verification of individuality. The cervix carcinoma cell line HELA is used in every AmpFLP as an internal standard. Searches revealing AmpFLP profiles of newly accessioned cell lines which are identical or similar to profiles already present in the database are further analyzed using side-by-side (GTG) 5 . 2, 13, 15, 16 Technical details have been summarized elsewhere. 14 The sequential use of minisatellite AmpFLP and (GTG) 5 multi-locus fingerprinting minimizes uncertainties in the fingerprint results arising via falsepositive matches by the former method.
Cytogenetic analysis
Details of methods used at the DSMZ for cytogenetic analysis of cell lines have been described elsewhere. 17 Briefly, adequately spread metaphase chromosome preparations are harvested from growing cell cultures and stored as suspensions in fixative (at −20°C) or on microscope slides (at −80°C). Cancer cytogenetics is a rapidly evolving field and cryopreservation allows continual review and update of results in the light of both technical and informational advances. The procedure currently used at the DSMZ combines G-banding with fluorescence in situ hybridization (FISH) to resolve select marker chromosomes, the combined data presented in standard format. 18 While cytogenetic analysis of cell lines at the DSMZ is first directed at characterizing disease-associated rearrangements, chiefly recurrent chromosome translocations, the resultant karyotypes usually include sufficient secondary rearrangements to provide useful descriptors. 19 Crucially, excluding autologous cell lines derived from the same patient and those with quasi-normal karyotypes, no two tumor cell lines in the DSMZ collection are karyotypically identical. The level of uniqueness achieved provides empirical justification for identifying individual cell lines cytogenetically. In addition to their virtue in identifying different cell lines and spotting cross-contamination, secondary changes arising in subclones may even allow autologous cell lines to be distinguished cytogenetically in the face of identical DNA profiles.
Cytogenetic authentication of human tumor cell lines at the DSMZ proceeds on the two fronts outlined below: positive verification of identity by reference to published karyotypic data; and detecting cross-contamination from untoward similarities with other cell lines previously karyotyped by us and recorded in our database.
Positive verification of authenticity:
In contrast to DNA profiling for which comparative data are seldom published, detailed cytogenetic data increasingly accompany original descriptions of cell lines. Positive authentication, therefore, necessarily relies on comparison with karyotypes provided by originators or other investigators. Ideally, current and previous karyotypes should match, although perfect congruence is rarely encountered. Discrepancies between early and subsequent passage karyotypes, although commonly attributed to 'instability in vitro', more often arise due to other causes, interpretational differences being the single most important factor. Hence, it is often worthwhile to refer to original pictorial karyotypes (karyograms) when pursuing authentication as photocopies seldom reproduce G-bands adequately. A second factor generating apparent differences between isolates of the same cell line appears to be outgrowth of cryptic subclones already present at establishment. Karyotypic evolution, when it does arise, often involves genotypically neutral gains in ploidy which generate massive changes in chromosome number which may hide untoward similarities.
Correspondence between actual and published karyotypes is strong evidence of identity, falling short of authenticity since at least 18% of new cell lines suffer cross-contamination at 'birth'. 20, 21 Conversely, significant discrepancies between observed and originator karyotypes do not always absolve originators from the charge of cross-contamination as, based on internal evidence, karyotypes purporting to represent new cell lines sometimes appear to represent primary material instead.
Uncovering cross-contaminations by database searches:
A second major source of karyotypic data for authentication involves searching our database of chromosome rearrangements analyzed in cell lines at the DSMZ, assembled in parallel with DNA fingerprints (see above). Part of the karyotypic section of this database is available online for interactive search (www.dsmz.de). Clearly, searching databases can only provide negative evidence of authenticity -untoward karyotypic similarities between cell lines constituting prima facie evidence of cross-contamination subject to verification by DNA fingerprinting. Unfortunately, ISCN karyotypes are not yet expressible in meaningful search algorithms, hampering detection of untoward matches in a database now comprising more than 500 tumor cell lines.
Conclusions:
Cytogenetic authentication of newer cell lines is usually relatively straightforward even among unkaryotyped examples, as well-provenanced material is usually available. Older 'classic' cell lines have often been karyotyped at some time although retrieval may overtax those with limited library access. Most problematic are older cell lines lacking karyotypes and whose originators may be difficult to trace. However, cytogenetics remains indispensable for verifying authenticity and should continue to play a useful although secondary role in detecting cross-contamination.
False leukemia-lymphoma cell lines
In 82 of the 550 (14.9%) cell lines analyzed we found unequivocal evidence of misidentification (Figure 2 , Tables 1-3) . Typical examples are a B cell instead of a T cell immunoprofile (eg KARPAS-45), untoward similarities in cytogenetic marker chromosomes (eg SPI-801), isoenzyme patterns specific for murine rather than human cells (eg REH-6), and discrepancies between cell lines allegedly established from the same patient (eg KMS-21-BM/PE). In most instances, the false cell lines showed the same DNA fingerprints as another, yet clearly authenticated cell line; in a few cases we could not determine the correct identity of the cross-contaminated cell line but had clear evidence that the cells at hand were false. Initially prior to the routine use of DNA fingerprinting, our cytogenetic analysis alone uncovered many cases of crosscontaminated cell lines based on the detection of marker chromosomes (eg LR10.6 and PBEI) and later as an adjunct to the DNA fingerprinting confirmed the identity of the impostor cells as the majority of the cross-contaminating cell lines were restricted to a handful of well-known and karyotypically wellcharacterized cell lines (Table 4) .
Upon detection of a cross-contaminated cell line displaying a fingerprint identical to that of an older well-authenticated cell line, the question arises whether an authentic prototype of the cross-contaminated cell line ever existed: ie did crosscontamination give rise to a virtual cell line only, or replace cultures of one which actually enjoyed independent existence and of which uncontaminated material may still exist? Percentages of cross-contaminated LL cell lines. Shown are the incidences of false LL cell lines which were obtained from the original investigators (n = 395) or from secondary sources (n = 155). Overall, 550 cell lines were examined by DNA fingerprinting, cytogenetic or immunophenotyping analysis. Karyotypic identity between original author's report and existing CCRF-CEM variant karyotypes; original author declined to provide cell line for DNA fingerprinting. f Cell lines BE-13 and PEER show identical DNA fingerprints and hence share common origin, presumably due to cross-contamination; however, their diploid and tetraploid karyotypes indicative of earlier and later passage numbers, respectively, suggest that BE-13 is derived from PEER, rather than vice-versa. g Cell line 1E8 is a subclone of cell line BLIN-1, both were found to be NALM-6; another BLIN-1 culture was cross-contaminated with K-562 (not listed). of any authentic prototype with reasonable certainty. The best evidence comes from those original publications in which a sufficiently informative karyotype of the purportedly new cell line (but displaying in fact the karyotype of the crosscontaminant) is available. Examples include: AG-F, CO, DAMI, JOSK-series, SPI-801/2, SR-91, TI-1, WSU-CLL, YJ and others. In other instances the original investigators could not provide authentic prototype cells.
Virtual cell lines
Misidentified cell lines (prototype exists)
In Table 2 , we listed those cell lines which were found to be false but of which we know that the correct cell lines (the prototypes) still exist and are available. However, in a number of cases, it appears improbable that the prototype cells may emerge. This table should alert the reader that while for example the real HPB-ALL, KE-37, L-540, U-937 and UT-7 (to name a few of the widely distributed lines) are certainly available, there are also impostor cultures under these designations 'going the rounds'. There are several hematopoietic diseases from which it is notoriously difficult to establish cell lines, in particular the mature B cell malignancies such as chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), plasma cell leukemia (PCL) and multiple myeloma and Hodgkin's disease (Table 3) . While there are number of bona fide myeloma-, PCL-and Hodgkin's disease-derived cell lines (reviewed in Refs 102 and 108), various cell lines which are in reality EBV+ B-LCLs have been described and are still being used as model systems for these diseases. The most difficult group are certainly the alleged B-CLL and HCL cell lines of which the majority are EBV+ B-LCLs (not listed in Table 3 , but summarized in Ref. 1).
Misclassified cell lines (non-malignant)
Most prolific contaminants
In the majority of cases, the cross-contaminating intruder could be identified. In more than 68% of the instances, these cross-contaminating cells were well-known 'classic' cell lines (Table 4 ). As these cell lines have all been established more than 25 years ago, they are now widely distributed throughout the scientific community and may be found in many laboratories working with cell lines. Furthermore, most are available from the major public cell line banks in Europe, USA and Japan. Finally, these cell lines grow very well, exacerbating dispersal, and have short doubling times leading to rapid overgrowth of the initial culture into which these cell lines were introduced. Besides DNA fingerprints, distinguishing chromosomal features when present may be used to identify human tumor cell lines. Cytogenetic identifiers for each of the seven most prolific cross-contaminants are presented in Table 4 and are uniquely represented in vitro, excepting del(2)(p23) in JUR-KAT which recurs in several cell lines. A further problem for cytogenetic authentication is posed by cell lines originally displaying normal or near-normal karyotypes of which CCRF-CEM is a prime example. Several subclones of the originally Table 4 Most prolific contaminants Except for OCI/AML2 (not listed here) all cell lines are widely spread throughout the scientific community and are available from the major public cell line banks. Cytogenetic particulars are based on karyotypic data representing cell lines analyzed at the DSMZ together with at least one independent sample analyzed elsewhere. Leukemia near-normal CCRF-CEM exist under a bewildering variety of aliases, each with its own apparently unique acquired chromosome rearrangement allowing these to pose as truly distinct cell lines. Although recurrent primary translocations are usually less informative for authentication, a notable exception involves the classic CML cell line K-562 which uniquely carries two marker chromosomes in which BCR-ABL fusion is effected by a cryptic t(9;22)(q34;q11) regionally amplified in tandem, 109 while U-937 (AF19-CALM) and REH (ETV6-AML1) are, respectively, unique and almost unique in vitro models for their respective gene fusions which, therefore, comprise useful descriptors.
Discussion
Impact of cross-contamination on scientific research
Confirming our previous data on a smaller sample of LL cell lines, we found that nearly every sixth cell line is "false", in the sense that the label on the flask or ampoule belies its true contents. First, we may conclude that the problem of crosscontamination, recognized first a generation ago by Walter Nelson-Rees and Flandermeyer 44 is chronic. Second, we can put some numbers on the problem. The actual levels of crosscontamination may be significantly higher than our estimate: at the DSMZ ascertainment relies on detecting untoward similarities (DNA profiling or karyotypic) between new acquisitions and cell lines already recorded in our databank which, numbering 490, represent only about 43% of those described hitherto (n = 1150), excluding subclones, Burkitt lymphoma and ATLL cell lines, as well as B-LCLs, the total based on the first attempt to list LL cell lines comprehensively, 1 updated by its author (HGD). Our estimate necessarily assumes equal levels of cross-contamination among circulating vs untested, often 'private', cell lines although there may be grounds for regarding this assumption as unwarranted. Third, surprisingly there is no significant difference in the level of cross-contamination observed between cell lines obtained from the originators and those received indirectly from secondary sources. This implies, somewhat counterintuitively, that most crosscontaminations occur during the attempted establishment of a new cell line as the alternative, that having successfully established new cell lines, originators then proceed fatally to cross-contaminate all their reserves, seems improbable.
In many instances, the purported new cell line was found to contain the same type of cells as the cross-contaminating cell line, eg the virtual cell line EU-1 (BCP-ALL) which is actually REH (BCP-ALL) or false PLB-985 (AML M4) which is HL-60 (AML M2) (see Table 1 ). This tendency has led some to conclude that it is immaterial whether, for example, cell line A or cell line B is used for experimentation as long as both belong to the same cell lineage. There are certainly instances where cell line authenticity may be of limited importance, eg toxicity screening. But there are also cases where this authenticity would be crucial, eg where a specific tumor has produced one or only few cell lines when unrepresentative data would produce major distortions. For example, despite a timely warning, a 'new entity of pre B-ALL' was defined on the basis of a specific chromosomal abnormality seen in three allegedly different BCP-ALL-derived cell lines; unfortunately two of the three cell lines (LR10.6 and PBEI) were the result of cross-contaminations with the third cell line studied (NALM-6); 110 hence, a new 'entity' has been defined on the basis of one cell line only.
On the other hand, there is certainly a substantial difference (at least for any hematological researcher) between, for example, the disease CMML (false cell line MDS) and the disease T-ALL (correct CCRF-CEM), NK-NHL (false NOI-90) and BCP-ALL (correct REH), T-ALL (false SPI-801) and CML-BC (correct K-562), and B-CLL (false WSU-CLL) and BCP-ALL (correct REH).
Furthermore, LL cell lines are in a state of perpetual reclassification in the light of the continual discovery of new leukemic subtypes whether on cytogenetic or other grounds. Incidentally, a cavalier attitude to labelling cell lines scarcely betokens good practice in the laboratory; rather, the better the research, the more important the need for authentic material and vice versa.
In general, it is unnecessary to assume that the vast majority of cross-contaminations were perpetrated deliberately but rather due to poor cell culture techniques. There is, nevertheless, one widely publicized case when a scientist inadvertently cross-contaminated cultures containing human Hodgkin's disease-derived cells with monkey cells, but continued to publish data gained with these cell lines as models for Hodgkin-Reed-Sternberg cells 96, 97 ( Table 3) . Regrettably, more recent examples of misconduct are not difficult to find: for example, the use of cell line HS-SULTAN as a myeloma cell line despite numerous proofs by various groups that it is a Burkitt lymphoma, or to apply WSU-CLL as a model for B-CLL in the face of its unmasking as the precursor B-ALL cell line REH. A bizarre incident is the reporting of two new monocytic cell lines derived from peripheral blood of two hematologically completely normal individuals with minor dermatologic diseases (psoriasis and atopic dermatitis) 74, 75 where both cell line karyotypes undoubtedly depicted U-937 monocytes confirmed by DNA fingerprinting at the DSMZ (Table 1) .
It is very difficult to quantify a problem which is partly submerged. Hence, we are in no position to be able to answer the question on the impact of cross-contaminated LL cell lines. There is certainly a significant percentage of research being done which produces data which simply cannot be extrapolated to the 'real' tumor, thus a waste of time, money and efforts. Furthermore, once published, scientific data are almost impossible to correct as there are simply no institutional mechanisms to cope with that.
Cell lines, properly used, are an invaluable asset to cancer research in general. But misuse saps confidence in cell lines as model systems as a whole which would lead to a lot of 'missed opportunities'. In contrast to other types of scientific misconduct or mistakes in publication, no recent instance of alerts to false cell lines, or their inappropriate use, have been followed by retraction of the offending publication.
Strong resistance to address the problem
Contrary to popular belief, scientists are institutionally motivated by desire for fame, as measured by publications in journals. Retraction implies incompetence or misconduct, synonymous with obloquy.
Once we detect a cross-contaminated cell line, it is our practice to inform the person from whom we had obtained this cell line and attempt to publish the finding. Here, we can discern three widely held positions. Perpetrators, ie originators of false cell lines, who usually adopt -at least initially -a defensive posture. The prevalent pressures (eg funding, reputation) encourage denial, self-deception, sometimes worse, maybe.
Second, the 'victims' -innocent recipients of false cell lines -may have published papers or obtained grants using false cell lines. But who wants to trash years of data? The results are denial or special pleading although one, of course, sympathizes with beginners unfamiliar with a literature which persistently remains reticent about the problem.
All this leaves less sympathy for journal editors and referees of publications and grants who are after all experienced scientists who should know the pitfalls. They should hold the torch high and light the way for the rest of us. But experts are all too often apathetic. Hence, reports listing instances of crosscontaminations tend to get buried in specialist journals when general journals would be more appropriate. Our guess is that they regard the cross-contamination issue as unworthy of their consideration. Alternatively, they could be worried about skeletons in their own cupboards or upsetting important colleagues.
In summary, therefore, the problem of false cell lines operates as a classic positive feedback loop, whereby information about false cell lines goes unreported or buried in specialist journals escaping the attention of unwary beginners who may later themselves become victims or even perpetrators.
What should be done about it?
John Masters and colleagues in London, have applied the latest forensic technology to the problem and shown that routine STR profiling may be an answer. 4, 112, 113 However, even if STR profiling becomes the standard, widespread adoption will take a long time without sufficient external pressures.
As for the preventive measures guarding against more and more false cell lines, some experts have advocated that each cell line should carry its own 'passport' documenting its history and proving its authenticity. 114 This is a counsel of perfection and, therefore, rather unrealistic in the absence of any means for its enforcement.
The best we can hope for is to persuade the persuaders, meaning those journal editors and grant reviewers to adopt key safeguards when setting out how papers should be written for inclusion in the journals they edit and how projects should be planned to merit financial support. Basically there are three safeguards: (1) for those describing new cell lines derived from patients, publications should prove identity of patient cells and cell lines via concordant side-by-side DNA fingerprints or identical marker chromosomes or truly specific molecular markers (eg banding patterns of immunoglobulin and T cell receptor gene rearrangement analysis); 115 thus, it should be possible for all subsequent users to verify authenticity; (2) by the same token, investigators using cell lines should be expected to disclose always their provenances in the Materials and Methods sections (which is all too often not the case); and (3) journals should request formal withdrawal of articles first describing false cell lines. Finally, a neglected point concerns availability. Sadly, many scientists are quite happy to publish new cell lines but are unwilling to supply them to others. This is not only mean spirited, it is risky because private cell lines evade independent analysis and authentication.
Summary
Over the last two to three decades there has been an explosion in our understanding of the biology, pathogenesis and treatment options for leukemias and lymphomas. Some of these advances have been made possible through the experimental use of continuous LL cell lines. As studies of freshly isolated patient samples are often hampered due to the difficulties inherent in isolating 'pure' malignant populations and the commonly rather limited number of available cells, many studies have relied predominantly on the analysis of malignancy-derived cell lines. But whether the cell lines examined truly represent their in vivo counterparts is almost always taken for granted.
On closer examination, the use of false LL cell lines may be seen to invalidate a significant percentage of scientific work, or at least cast doubts on the relevance of these in vitro results to the cell type or tumor in vivo. Ultimately, use of cross-contaminated cell lines is a waste of human and material resources.
It appears that the bulk of cross-contaminations occur during the attempts of culturing malignant cells in efforts to establish new cell lines. Henceforth, it should be mandatory to prove the proper derivation of each new cell line by comparing DNA fingerprints or karyotypes of the patient's primary cells and the cultured cells.
